06/10/2026 Firmonertinib failed to demonstrate statistically significant PFS benefit in 1L EGFR Exon 20ins NSCLC Firmonertinib failed to demonstrate statistically significant PFS benefit in 1L EGFR Exon 20ins NSCLC (Ref) ArriVent announced a program update from the Phase 3 FURVENT trial evaluating firmonertinib (EGFR-TKI) as first-line treatment for patients with EGFR exon 20 insertion-mutant NSCLC. While the study did not meet its primary endpoint of progression-free surviva

12/08/2026 NMPA approves ivonescimab + chemo for first‑line advanced squamous NSCLC Zipalertinib Combo Achieves PFS Milestone in EGFR Exon 20 NSCLC, FDA Filing Planned NMPA approves ivonescimab + chemo for first‑line advanced squamous NSCLC (Ref) China’s NMPA approved Akeso Bio & Summit Therapeutics' ivonescimab (PD-1 x VEGF) in combination with chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC) The approval was based on the signi

14/07/2026 FDA frants Fast Track Designation to SOTIO’s SOT109 (CDH17-targeting) ADC for advanced Colorectal Cancer FDA grants full approval to selpercatinib for RET fusion positive solid tumors AstraZeneca secures global rights to Zegfrovy, first oral EGFR exon 20 NSCLC therapy, in $600M upfront deal with Dizal In a Ph3 trial, HBI-8000 + nivolumab improved PFS vs nivolumab + placebo, for advanced Melanoma FDA approved first generics of Gilotrif (afatinib) for EGFR‑mutant and